cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1175Research ArticleОБЗОРЫREVIEWSОбзор исследований, оценивающих результаты применения стентов у больных ишемической болезнью сердцаStents in coronary heart disease patients: review of the studies availableБокерияЛ. А.BokeriyaL. A.

Москва

Moscow

СтупаковИ. Н.StupakovI. N.

Москва

Moscow

СамородскаяИ. В.SamorodskayaI. V.

Москва

Moscow

samor2000@list.ruНаучный центр сердечно-сосудистой хирургии им. А.Н.БакулеваA.N. Bakulev Research Center for Cardiovascular Surgery2009200220098199105Copyright © Бокерия Л.А., Ступаков И.Н., Самородская И.В., 20092009Бокерия Л.А., Ступаков И.Н., Самородская И.В.Bokeriya L.A., Stupakov I.N., Samorodskaya I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1175

В обзорной статье представлены результаты рандомизированных исследований, регистров, мета-анализов, систематических обзоров, проведенных другими авторами, оценивающих клинически значимые исходы лечения: смертность, частоту последующих инфарктов миокарда, реваскуляризаций, частоту тромбозов стента среди пациентов с различными нозологическими формами ишемической болезни сердца, которым имплантировали стенты без покрытия, стенты с покрытием sirolimus и стенты с покрытием paclitaxel.

The review presents the results of published randomized trials, registers, meta-analyses, and systematic reviews on the following clinical outcomes: mortality, incidence of repeat myocardial infarctions, repeat revascularizations and stent thromboses among patients with various forms of coronary heart disease, after implantation of noneluting, sirolimus-eluting and paclitaxel-eluting stents.

стенты коронарныеишемическая болезнь сердцарандомизированные исследованиярегистрмета-анализcoronary stentscoronary heart diseaserandomized trialsregistermeta-analysisReferencesДоказательная меддЦйна и сердечно-сосудистые заболевания. Под редакцией академика РАМН Бокерия Л.А. Москва НЦССХ 2006.Доказательная меддЦйна и сердечно-сосудистые заболевания. Под редакцией академика РАМН Бокерия Л.А. Москва НЦССХ 2006.Windecker S, Simon R; Lins M, at al. Randomized Comparison of a Titanium-Nitride-Oxide—Coated Stent With a Stainless Steel Stent for Coronary Revascularization The TiNOX Trial. Circulation2005; 111: 2617-22.Windecker S, Simon R; Lins M, at al. Randomized Comparison of a Titanium-Nitride-Oxide—Coated Stent With a Stainless Steel Stent for Coronary Revascularization The TiNOX Trial. Circulation2005; 111: 2617-22.Pache J, Dibra A, Meliilli J, et al. Drug-eluting stents compared with thin-Strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005; 26(13): 1262-8.Pache J, Dibra A, Meliilli J, et al. Drug-eluting stents compared with thin-Strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005; 26(13): 1262-8.Dawkins KD. TAXUS VI; TAXUS MR Stent in Complex Lesions. 3-Year Clinical Results. Доклад: EuroPCR 2006 — The Paris Course on Revascularization, источник: www.medscape.comDawkins KD. TAXUS VI; TAXUS MR Stent in Complex Lesions. 3-Year Clinical Results. Доклад: EuroPCR 2006 — The Paris Course on Revascularization, источник: www.medscape.comFajadet J, Wijns W, Laarman G-J, et al. Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions (ENDEAVOR II Trial). Circulation 2006; 114: 798-806.Fajadet J, Wijns W, Laarman G-J, et al. Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions (ENDEAVOR II Trial). Circulation 2006; 114: 798-806.Suttorp MJ, Laarman GJ, Rahel BM, et al. Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II). Circulation 2006; 114: 921-8. "Suttorp MJ, Laarman GJ, Rahel BM, et al. Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II). Circulation 2006; 114: 921-8. "Menichelli M SESAMI: Sirolimus Stent vs Bare Stent in Acute Myocardial Infarction. Доклад на EuroPCR 2006. The Paris Course on Revascularization, источник: www.medscape.comMenichelli M SESAMI: Sirolimus Stent vs Bare Stent in Acute Myocardial Infarction. Доклад на EuroPCR 2006. The Paris Course on Revascularization, источник: www.medscape.comWeisz G, Leon MB, Holmes DR, et al. Two-Year Outcomes After Sirolimus-Eluting Stent Implantation Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial. JACC 2006; 47(7): 1350-5.Weisz G, Leon MB, Holmes DR, et al. Two-Year Outcomes After Sirolimus-Eluting Stent Implantation Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial. JACC 2006; 47(7): 1350-5.Serruys PW, Long-Term Adverse Events With Drug-Eluting Stents After ST EMI. Am J Cardiol 2007; 99: 1027-32.Serruys PW, Long-Term Adverse Events With Drug-Eluting Stents After ST EMI. Am J Cardiol 2007; 99: 1027-32.Voudris V, Alexopoulos E, Karyofillis P, et al. Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry—acute results and mid-term outcomes: a single-center experience. J Invasive Cardiol 2005 Aug; 17(8): 401-5.Voudris V, Alexopoulos E, Karyofillis P, et al. Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry—acute results and mid-term outcomes: a single-center experience. J Invasive Cardiol 2005 Aug; 17(8): 401-5.Valgimigli M, van Miegliem CA, Ong AT, et al. Short- and longterm clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation2005; 111: 1383-9.Valgimigli M, van Miegliem CA, Ong AT, et al. Short- and longterm clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation2005; 111: 1383-9.Ong AT, Daemen J, van Hout BA, et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. Em Heart J 2006; 27(24): 2996-3003.Ong AT, Daemen J, van Hout BA, et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. Em Heart J 2006; 27(24): 2996-3003.Kaiser C, Bruimer-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitflts Trial (BASKET). Lancet 2005; 366: 921-9.Kaiser C, Bruimer-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitflts Trial (BASKET). Lancet 2005; 366: 921-9.Abbott JD, Williams DO. DEScover Registry: Drug-Eluting Stents vs Bare-Metal Stents. 1-Year Clinical Results. Medscape Cardiology 2007. http://www.medscape.com/viewarticle/554512Abbott JD, Williams DO. DEScover Registry: Drug-Eluting Stents vs Bare-Metal Stents. 1-Year Clinical Results. Medscape Cardiology 2007. http://www.medscape.com/viewarticle/554512James S. SCAAR — Long term mortality after drug eluting stents in Sweden, an additional year of follow-up. (источник информации ESC Congress Reports, 2007, wwwescardio.org).James S. SCAAR — Long term mortality after drug eluting stents in Sweden, an additional year of follow-up. (источник информации ESC Congress Reports, 2007, wwwescardio.org).Maeng M. Danish Registry Points to Increased MI After 12 Months With DES, but Optimism Prevails 2007. сайт www.medscape.comMaeng M. Danish Registry Points to Increased MI After 12 Months With DES, but Optimism Prevails 2007. сайт www.medscape.comSerruys PW, Van EsG-A, Stoll H-P, et al. Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents. Five-Year Results of the RAVEL Trial. JACC 2007; 50M299-304.Serruys PW, Van EsG-A, Stoll H-P, et al. Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents. Five-Year Results of the RAVEL Trial. JACC 2007; 50M299-304.de Lezo J, Medina A, Pan M, et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study (abstr). JACC 2005; 45: 75A.de Lezo J, Medina A, Pan M, et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study (abstr). JACC 2005; 45: 75A.Kastrati A, Meliilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial (ISAR-DESIRE). JAMA 2005; 293: 165-71.Kastrati A, Meliilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial (ISAR-DESIRE). JAMA 2005; 293: 165-71.Dibra A, Kastrati A, Meliilli J, et al. Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients. (ISAR-DIABETES). N Engl J Med 2005; 353; 663-70.Dibra A, Kastrati A, Meliilli J, et al. Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients. (ISAR-DIABETES). N Engl J Med 2005; 353; 663-70.Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization (SIRTAX). N Engl J Med 2005; 353: 653-62.Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization (SIRTAX). N Engl J Med 2005; 353: 653-62.Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXI trial. JACC 2005; 45: 308-11.Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXI trial. JACC 2005; 45: 308-11.Cervinka P, Costa MA, Angiolillo DJ, et al. Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study. Catheter Cardiovasc Interv 2006; 67: 846-51.Cervinka P, Costa MA, Angiolillo DJ, et al. Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study. Catheter Cardiovasc Interv 2006; 67: 846-51.Han YL, Wang XZ, Jing QM, et al. Comparison of rapamycin and paclitaxel eluting stent in patients with multi-vessel coronary disease (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34: 123-6.Han YL, Wang XZ, Jing QM, et al. Comparison of rapamycin and paclitaxel eluting stent in patients with multi-vessel coronary disease (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34: 123-6.Meliilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels (ISAR-SMART). Eur Heart J 2006; 27: 260-6.Meliilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels (ISAR-SMART). Eur Heart J 2006; 27: 260-6.Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease (LONG DES II). Circulation 2006; 114: 2148-53.Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease (LONG DES II). Circulation 2006; 114: 2148-53.Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxeleluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895-904.Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxeleluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895-904.Zhang Q, Zhang RY, Zhang JS, et al. One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. Chin Med J (Engl) 2006; 119: 165-8.Zhang Q, Zhang RY, Zhang JS, et al. One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. Chin Med J (Engl) 2006; 119: 165-8.Petronio AS, De Carlo M, Branchitta G, et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. JACC 2007; 49: 539-46.Petronio AS, De Carlo M, Branchitta G, et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. JACC 2007; 49: 539-46.Pan M, Su6rez de Lezo J, Medina A, et al. Drug-eluting Stents for the Treatment of Bifurcation Lesions: A Randomized Comparison Between Paclitaxel and Sirolimus Stents. Am Heart J 2007; 153(1): 15. el-15.e7. to: http://www.medscape.comPan M, Su6rez de Lezo J, Medina A, et al. Drug-eluting Stents for the Treatment of Bifurcation Lesions: A Randomized Comparison Between Paclitaxel and Sirolimus Stents. Am Heart J 2007; 153(1): 15. el-15.e7. to: http://www.medscape.comMoses JW, Stone GW, Nikolsky E, et al. DrugHjluting Stents in the Treatment of Intermediate Lesions. Pooled Analysis From Four Randomized Trials. JACC 2006; 47(11): 2164-71.Moses JW, Stone GW, Nikolsky E, et al. DrugHjluting Stents in the Treatment of Intermediate Lesions. Pooled Analysis From Four Randomized Trials. JACC 2006; 47(11): 2164-71.Holmes DR, Moses JW, Schofer J, et al. Cause of death with bare metal and sirolimus-eluting stents. Eur Heart J 2006; 27(23): 2815-22.Holmes DR, Moses JW, Schofer J, et al. Cause of death with bare metal and sirolimus-eluting stents. Eur Heart J 2006; 27(23): 2815-22.- Nordmaim AJ. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27(23): 2784—814.- Nordmaim AJ. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27(23): 2784—814.Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119(12): 1056-61.Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119(12): 1056-61.. Serruys PW, Kutryk MJB, Ong ATL. Coronary-Artery Stents. NEJM 2006; 354(2):483-95.. Serruys PW, Kutryk MJB, Ong ATL. Coronary-Artery Stents. NEJM 2006; 354(2):483-95.Spaulding C, Daemen J, Boersma E. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med2007; 356: 989-97.Spaulding C, Daemen J, Boersma E. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med2007; 356: 989-97.Kastrati A, Meliilli J, Pache J. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-9.Kastrati A, Meliilli J, Pache J. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-9.Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Eleart J. Сайт doi:10.1093/eurheartj/elmi402Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Eleart J. Сайт doi:10.1093/eurheartj/elmi402Pasceri V, Patti G, Speciale G, et al. Meta-Analysis of Clinical Trials on Use of Drug-Eluting Stents for Treatment of Acute Myocardial Infarction. Am Heart J 2007; 153(5): 749-54.Pasceri V, Patti G, Speciale G, et al. Meta-Analysis of Clinical Trials on Use of Drug-Eluting Stents for Treatment of Acute Myocardial Infarction. Am Heart J 2007; 153(5): 749-54.Sclnimig A, Dibra A, Windecker S, et al. A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. JACC 2007; 50(14): 1373-80.Sclnimig A, Dibra A, Windecker S, et al. A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. JACC 2007; 50(14): 1373-80.Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs. paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294: 819-25.Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs. paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294: 819-25.Herrmann IIC. Drug-Eluting Stent Thrombosis: Weighing the Evidence. J Watch Cardiology 2006. источник: www.medscape.comHerrmann IIC. Drug-Eluting Stent Thrombosis: Weighing the Evidence. J Watch Cardiology 2006. источник: www.medscape.comHerrmann H.C. The Stent Controversy Continues. J Watch 2007; 6(2) ©2007 Massachusetts Medical Society Posted 03/14/2007 источник: www.medscape.comHerrmann H.C. The Stent Controversy Continues. J Watch 2007; 6(2) ©2007 Massachusetts Medical Society Posted 03/14/2007 источник: www.medscape.comHerrmann HC. Does PCI Improve Survival and Prevent MI in Stable CAD? J Watch 2007; 6(3) ©2007 Massachusetts Medical Society. Posted 04/12/2007 источник: www.medscape.comHerrmann HC. Does PCI Improve Survival and Prevent MI in Stable CAD? J Watch 2007; 6(3) ©2007 Massachusetts Medical Society. Posted 04/12/2007 источник: www.medscape.comStone GW, Moses JW, Ellis SG. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.Stone GW, Moses JW, Ellis SG. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.Kandzari DE. Tuttle RH, Zidar JP, Jollis JG,Temporal Trends in Target Vessel Revascularization in Clinical Practice: Long-Term Outcomes following Coronary Stenting from the Duke Database for Cardiovascular Disease. J Invasive Cardiol 2006; 18(9): 398-402.Kandzari DE. Tuttle RH, Zidar JP, Jollis JG,Temporal Trends in Target Vessel Revascularization in Clinical Practice: Long-Term Outcomes following Coronary Stenting from the Duke Database for Cardiovascular Disease. J Invasive Cardiol 2006; 18(9): 398-402.Steg G. DES Fall From GRACE in STEMI: Patients Face More Than Fourfold Higher Risk of Death Than Bare-Metal-Stent-Treated Patients. Eur Society of Cardiology Congress 2007. (Universitii de Paris XII, France).www.medscape.comSteg G. DES Fall From GRACE in STEMI: Patients Face More Than Fourfold Higher Risk of Death Than Bare-Metal-Stent-Treated Patients. Eur Society of Cardiology Congress 2007. (Universitii de Paris XII, France).www.medscape.comPark DW, Park SW, Lee SW. Frequency of coronary arterial late angiographic stent thrombosis (LAST) in the first six months: outcomes with drug-eluting stents versus bare metal stents. Am J Cardiol 2007; 99(6): 774-8.Park DW, Park SW, Lee SW. Frequency of coronary arterial late angiographic stent thrombosis (LAST) in the first six months: outcomes with drug-eluting stents versus bare metal stents. Am J Cardiol 2007; 99(6): 774-8.James S. SCAAR — Long term mortality after drug eluting stents in Sweden, an additional year of follow-up. (источник информации: BSC Congress Reports 2007; www.escardio.org).James S. SCAAR — Long term mortality after drug eluting stents in Sweden, an additional year of follow-up. (источник информации: BSC Congress Reports 2007; www.escardio.org).Silverman Mark E. Coronary-Artery Stents: To the Editor. NEJM 2006; 354: 2076-8.Silverman Mark E. Coronary-Artery Stents: To the Editor. NEJM 2006; 354: 2076-8.

The authors declare that there are no conflicts of interest present.